P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption.
P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption.
复制标题
DOI：
10.1371/journal.pone.0023199
复制
发表时间：
2011
期刊：
影响因子：
3.7
通讯作者：
Myoui A
中科院分区：
文献类型：
--
作者：
Tao H;Okamoto M;Nishikawa M;Yoshikawa H;Myoui A
p38 丝裂原激活蛋白激酶 (MAPK) 在信号通路下游发挥作用，其中包括 NF-κB 受体激活剂 (RANK)，破骨细胞形成和激活的强大诱导剂。我们研究了 p38 MAPK 在体外甲状旁腺激素相关蛋白 (PTHrP) 诱导的破骨细胞生成和体内 PTHrP 诱导的骨吸收中的作用。通过在体外破骨细胞生成试验中计数耐酒石酸酸性磷酸酶阳性多核细胞（TRAP 阳性 MNC）的数量来评估 FR167653 抑制破骨细胞形成的能力。通过检测sRANKL和M-CSF刺激的骨髓巨噬细胞（BMM）中c-Fos和活化T细胞核因子c1（NFATc1）的表达水平，以及在FR167653存在的情况下检测PTHrP刺激的骨髓基质细胞中骨保护素（OPG）和RANKL的表达水平来评估其机制。通过在颅骨皮下注射 PTHrP 的骨吸收小鼠模型中，通过放射线测量骨吸收面积并计算颅骨中每单位骨组织面积的破骨细胞数量来评估 FR167653 对骨吸收的功能。还记录了全血离子钙水平。 FR167653 抑制 PTHrP 诱导的破骨细胞形成以及 PTHrP 诱导的骨髓巨噬细胞中的 c-Fos 和 NFATc1 表达，但不抑制 PTHrP 处理的原代骨髓基质细胞中 RANKL 和 OPG 的表达水平。此外，FR167653的治疗显着降低了体内骨吸收面积和破骨细胞数量。全身性高钙血症也受到部分抑制。 FR167653 对 p38 MAPK 的抑制可阻断 PTHrP 诱导的体外破骨细胞生成和 PTHrP 诱导的体内骨吸收，表明 p38 MAPK 信号通路在 PTHrP 诱导的破骨细胞骨吸收中发挥重要作用。
p38 mitogen-activated protein kinase (MAPK) acts downstream in the signaling pathway that includes receptor activator of NF-κB (RANK), a powerful inducer of osteoclast formation and activation. We investigated the role of p38 MAPK in parathyroid hormone related protein (PTHrP)-induced osteoclastogenesis in vitro and PTHrP-induced bone resorption in vivo. The ability of FR167653 to inhibit osteoclast formation was evaluated by counting the number of tartrate-resistant acid phosphatase positive multinucleated cells (TRAP-positive MNCs) in in vitro osteoclastgenesis assays. Its mechanisms were evaluated by detecting the expression level of c-Fos and nuclear factor of activated T cells c1 (NFATc1) in bone marrow macrophages(BMMs) stimulated with sRANKL and M-CSF, and by detecting the expression level of osteoprotegerin (OPG) and RANKL in bone marrow stromal cells stimulated with PTHrP in the presence of FR167653. The function of FR167653 on bone resorption was assessed by measuring the bone resorption area radiographically and by counting osteoclast number per unit bone tissue area in calvaria in a mouse model of bone resorption by injecting PTHrP subcutaneously onto calvaria. Whole blood ionized calcium levels were also recorded. FR167653 inhibited PTHrP-induced osteoclast formation and PTHrP-induced c-Fos and NFATc1 expression in bone marrow macrophages, but not the expression levels of RANKL and OPG in primary bone marrow stromal cells treated by PTHrP. Furthermore, bone resorption area and osteoclast number in vivo were significantly decreased by the treatment of FR167653. Systemic hypercalcemia was also partially inhibited. Inhibition of p38 MAPK by FR167653 blocks PTHrP-induced osteoclastogenesis in vitro and PTHrP-induced bone resorption in vivo, suggesting that the p38 MAPK signaling pathway plays a fundamental role in PTHrP-induced osteoclastic bone resorption.
登录
查看更多内容
影响因子：
4.8
作者：
Li, XT;Udagawa, N;Takahashi, N
通讯作者：
Takahashi, N
影响因子：
--
作者：
Nishikawa, M;Myoui, A;Yoshikawa, H
通讯作者：
Yoshikawa, H
影响因子：
6.2
作者：
Morony, S;Capparelli, C;Dunstan, CR
通讯作者：
Dunstan, CR
影响因子：
4.3
作者：
Cau, Jerome;Favreau, Frederic;Hauet, Thierry
通讯作者：
Hauet, Thierry
影响因子：
4.2
作者：
Hou, ZS;Yanaga, K;Kanematsu, T
通讯作者：
Kanematsu, T